Ziopharm oncology inc (ZIOP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10Sep'09
Collaboration revenue

-

-

-

-

-

0

0

0

146

1,597

1,598

1,597

1,597

1,597

1,598

1,697

1,969

1,919

1,869

272

272

340

633

200

200

200

200

200

200

200

200

200

200

200

200

200

67

-

-

0

Operating expenses:
Research and development

12,706

10,216

8,641

9,998

9,476

8,199

8,263

7,489

10,183

11,181

11,105

10,831

11,967

9,389

8,975

129,228

10,199

8,142

16,970

7,424

74,249

8,085

9,733

8,346

6,542

2,718

6,247

14,775

19,112

34,982

16,215

18,264

13,985

12,650

10,667

9,125

24,641

5,711

2,222

1,231

General and administrative

5,954

5,820

4,807

4,755

4,145

4,563

4,307

4,889

6,159

3,852

3,571

3,780

3,595

3,319

3,537

3,711

3,810

3,259

3,065

7,073

4,250

2,851

2,842

3,031

3,442

4,201

3,068

3,721

4,671

4,061

5,712

4,902

4,848

3,967

3,742

3,923

3,352

2,789

2,894

1,339

Total operating expenses

18,660

16,036

13,448

14,753

13,621

12,762

12,570

12,378

16,342

15,033

14,676

14,611

15,562

12,708

12,512

132,939

14,009

11,401

20,035

14,497

78,499

10,936

12,575

11,377

9,984

6,919

9,315

18,496

23,783

39,043

21,927

23,166

18,833

16,617

14,409

13,048

27,993

8,500

5,116

2,570

Loss from operations

-18,660

-16,036

-13,448

-14,753

-13,621

-12,762

-12,570

-12,378

-16,196

-13,436

-13,078

-13,014

-13,965

-11,111

-10,914

-131,242

-12,040

-9,482

-18,166

-14,225

-78,227

-10,596

-11,942

-11,177

-9,784

-6,719

-9,115

-18,296

-23,583

-38,843

-21,727

-22,966

-18,633

-16,417

-14,209

-12,848

-27,926

-8,500

-5,116

-2,570

Other income, net

367

290

203

133

187

169

150

164

148

166

175

86

38

32

39

42

21

6

-4

14

-4

1

2

1

-9

-391

-191

7

-4

52

-42

3

-26

13

19

9

-2

7

13

-1

Non-cash inducement warrant expense

-

-

60,751

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

194

5,847

5,600

82

-1,793

-7,407

-403

10,788

8,566

3,945

-650

-5,811

3,160

13,388

2,115

-11,080

-3,712

14,142

-304

Change in fair value of derivative liabilities

-

-

-

-

-

112

-165

183

28

-3

202

66

-1,560

-

21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-18,293

-15,746

-73,996

-14,620

-13,434

194,538

-12,585

-12,031

-16,020

-13,273

-12,701

-12,862

-15,487

-11,224

-10,854

-131,200

-12,019

-9,476

-18,170

-14,211

-78,231

-10,401

-6,093

-5,576

-9,711

-8,903

-16,713

-18,692

-12,799

-30,225

-17,824

-23,613

-24,470

-13,244

-802

-10,724

-39,008

-12,205

9,039

-2,875

Preferred stock dividends

-

-

-

-

-

342

6,074

5,462

5,120

4,999

4,903

4,865

4,171

-

3,591

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) applicable to common stockholders

-

-

-73,996

-14,620

-

194,538

-18,659

-17,493

-21,140

-18,272

-17,604

-17,727

-19,658

-14,756

-14,445

-131,200

-12,019

-

-18,170

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share

-0.09

-

-0.43

-0.09

-0.08

-

-0.13

-0.12

-0.15

-

-0.13

-0.13

-0.15

-

-0.11

-1.01

-0.09

-0.02

-0.14

-0.11

-0.69

-0.09

-0.06

-0.06

-0.10

-0.09

-0.20

-0.22

-0.15

-0.37

-0.23

-0.30

-0.32

-

-

-

-0.65

-

-

-

Net income (loss) per share - basic

-

-

-

-

-

1.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.01

-0.16

-

-0.26

0.21

-0.13

Net income (loss) per share - diluted

-

-

-

-

-

1.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.01

-0.16

-

-0.26

0.19

-0.13

Weighted average common shares outstanding used to compute basic and diluted net loss per share

199,814

-

170,613

160,789

160,640

-

141,185

141,017

140,853

-

140,632

135,630

130,696

-

130,496

130,385

130,157

130,108

129,732

128,413

113,410

103,442

100,428

100,422

100,229

94,622

83,161

83,082

82,906

81,379

78,670

78,514

75,620

-

-

-

60,412

-

-

-

Weighted average common shares outstanding used to compute basic net income (loss) per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68,104

67,229

-

47,426

42,364

21,759

Weighted average common shares outstanding used to compute diluted net income (loss) per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68,104

67,229

-

47,426

48,822

21,759